How Perimenopause Affects Your Cognitive Health

Perimenopause — the transition leading to menopause, typically beginning in the mid-to-late 40s and lasting 4–8 years on average — is associated with documented, measurable cognitive changes in many women. The SWAN (Study of Women's Health Across the Nation) study, one of the largest longitudinal studies of the menopausal transition, found that verbal learning and memory, processing speed, and working memory all showed measurable declines during the perimenopause period, with partial recovery in early postmenopause for some women.

The cognitive effects of perimenopause are primarily driven by fluctuating and declining estrogen levels. Estrogen promotes glucose uptake in the brain, reduces neuroinflammation, and supports the production of acetylcholine — a neurotransmitter critical for memory and attention. As estrogen fluctuates during perimenopause, brain energy metabolism and cholinergic function are correspondingly disrupted, producing cognitive symptoms that track with hormone levels.

Research from Roberta Brinton's group at the University of Arizona has used neuroimaging to document that estrogen decline during perimenopause is associated with reduced glucose metabolism in the brain regions most vulnerable in Alzheimer's disease — specifically the posterior cingulate cortex and precuneus. This has led to the hypothesis that perimenopause may represent a critical window for Alzheimer's disease risk, where the removal of estrogen's neuroprotective effects initiates processes that play out over subsequent decades.

Verbal learning and memory, processing speed, and attention are the domains most consistently affected in perimenopause research. Word-finding difficulty — struggling to retrieve specific words that feel just out of reach — is among the most commonly reported and distressing cognitive symptoms during this transition. Working memory (holding and using information in real time) also shows vulnerability.

Critically, the research suggests that these changes are largely reversible for most women during the early postmenopausal period. The SWAN study found that cognitive performance in early postmenopause often returned toward premenopausal levels, suggesting that the perimenopause transition itself — rather than postmenopause — is the period of greatest cognitive vulnerability for many women.

Sleep disruption is the most important modifiable factor during perimenopause from a cognitive health perspective. Vasomotor symptoms (hot flashes and night sweats) — which affect up to 80% of perimenopausal women — frequently disrupt sleep. Sleep disruption impairs cognitive function directly and prevents the glymphatic clearance of metabolic waste from the brain. Effective management of vasomotor symptoms, whether through hormone therapy or non-hormonal approaches, can substantially improve sleep quality and secondarily improve cognitive symptoms.

Regular aerobic exercise has particularly strong evidence for cognitive benefit during the menopausal transition. Exercise promotes brain-derived neurotrophic factor (BDNF) production, supports cerebrovascular health, and improves sleep quality — addressing multiple cognitive risk pathways simultaneously. A 2022 review in Menopause found consistent cognitive benefits of aerobic exercise during and after the menopausal transition.

The evidence on hormone therapy and cognition during perimenopause is evolving. Current evidence supports that hormone therapy initiated during perimenopause (the timing hypothesis) may have cognitive benefits, while initiation after 60 or more than 10 years post-menopause may not. This is a complex, individual decision best made with a menopause specialist who is familiar with the current evidence.

The perimenopausal period is cognitively confusing for many women precisely because it involves genuine cognitive symptoms that overlap with early dementia symptoms — making it hard to know whether what you are experiencing is hormonal or something more. An objective daily trend line is the most direct way to address this ambiguity.

If cognitive performance dips during the symptomatic perimenopause period and begins recovering in early postmenopause, the trend data shows this — providing concrete reassurance that the symptoms were hormonally driven and not pathological. If cognitive performance dips and continues declining in postmenopause, that is a different signal requiring clinical evaluation. Keel's longitudinal data converts what is often a frightening, ambiguous experience into interpretable evidence that can inform conversations with physicians about next steps.